Asian Paints
2659.2 -27.50
Cipla
1387.9 -13.40
Eicher Motors
7050 -20.00
Nestle India
1398.9 12.70
Grasim Inds
3050.1 -37.60
Hindalco Inds.
1062.4 -30.20
Hind. Unilever
2110.1 -11.40
ITC
279.45 -1.25
Trent
2724.1 -50.10
Larsen & Toubro
3875.5 -77.70
M & M
2966 -74.50
Reliance Industries
1263.3 -27.70
Tata Consumer
1107 -23.90
Tata Motors PVeh
389 -8.80
Tata Steel
202.72 -4.05
Wipro
181.76 -16.61
Apollo Hospitals
8358.5 54.00
Dr Reddy's Labs
1275.6 -2.60
Titan Company
4192.4 -67.80
SBI
981.95 4.25
Shriram Finance
896.65 -26.65
Bharat Electron
412.95 4.75
Kotak Mah. Bank
377.1 -0.35
Infosys
1187.6 -9.90
Bajaj Finance
871.1 -18.30
Adani Enterp.
2970 -78.20
Sun Pharma.Inds.
1788.8 6.60
JSW Steel
1260.7 -23.30
HDFC Bank
738.65 -8.40
TCS
2151.4 -47.50
ICICI Bank
1250.2 -11.90
Power Grid Corpn
290.3 4.65
Maruti Suzuki
12912 -138.00
Axis Bank
1268.1 -4.20
HCL Technologies
1151.3 -3.40
O N G C
264.65 -0.10
NTPC
362.4 0.75
Coal India
464.9 -7.40
Bharti Airtel
1813.3 15.10
Tech Mahindra
1503.4 19.90
Jio Financial
228.86 -8.03
Adani Ports
1805 -19.20
HDFC Life Insur.
564.55 -10.75
SBI Life Insuran
1764.4 -18.40
Max Healthcare
1007.45 30.20
UltraTech Cem.
10795 -117.00
Bajaj Auto
10231 -111.00
Bajaj Finserv
1674.6 -28.60
Interglobe Aviat
4359.7 -121.60
Eternal
248.3 -8.20
Panacea Biotec announced the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll' in sub-Saharan Africa (sSA) and to facilitate its broader global use. The four-year initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union and aligns with the EDCTP3 mission to combat Neglected Tropical Diseases (NTDs), including dengue fever, and seeks to reduce the disease burden across Africa.
The DENSTAR project is coordinated by the 'Sclavo Vaccines Association', a non-profit organization based in Siena (Italy) devoted to support vaccine research and development in developing countries. The DENSTAR consortium unites 10 Partners from 9 countries across Europe, Africa, the United States, India and South Korea which comprises of universities, research organizations, a biotech company and a non profit organization, bringing together experts, researchers, regulators, healthcare practitioners. Panacea Biotec being the developer of DengiAll', a tetravalent dengue vaccine targeting all four virus serotypes and currently in late-stage development in India, is a key partner of the DENSTAR consortium. This diverse and complementary consortium embodies a great public-private partnership, fully aligned with the DENSTAR project's goal to promote broader use of DengiAll' in Africa and globally, contributing to equitable access to safe and effective dengue prevention tools.